An investigation on behalf of investors of Incyte Corporation (NASDAQ:INCY) shares over potential securities laws violations by Incyte Corporation and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Incyte Corporation (NASDAQ:INCY) concerning whether a series of statements by Incyte Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Wilmington, DE based Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States.

On April 14, 2017, Incyte Corporation revealed that the U.S. Food and Drug Administration ('FDA') had rejected the new drug application for baricitinib, a once-daily rheumatoid arthritis treatment developed in collaboration with Eli Lilly and Company. Incyte Corporation informed investors that the FDA asked for additional data to 'characterize safety concerns across treatment arms' and to determine 'the most appropriate doses.'

On April 19, 2018, the U.S. Food and Drug Administration ('FDA') issued a briefing document in advance of the April 23, 2018 meeting of the FDA's Arthritis Advisory Committee, stating, in part, that Incyte's rheumatoid arthritis drug, baricitinib, poses serious risks of deadly blood clots at higher doses.